FTC to Allow Tepezza Manufacturer to be Bought By Amgen Amid Growing Hearing Loss Litigation
The deal seeks to prevent Amgen from leveraging its near-monopoly on Tepezza and other Horizon drugs into an overwhelming competitive advantage.
The deal seeks to prevent Amgen from leveraging its near-monopoly on Tepezza and other Horizon drugs into an overwhelming competitive advantage.
Acquiring Tepezza and Krystexxa would give Amgen a monopoly on those treatments, which it could then use to smother competition, the FTC warns
Lawsuit alleges no warnings or information was provided about the risk of hearing damage from Tepezza, which could have been avoided with medical monitoring
Horizon Pharmaceuticals claims the Tepezza hearing loss lawsuit is preempted by federal law because the manufacturer would have been unlikely to change the label warnings without FDA permission.
Horizon has objected to the call to consolidate Tepezza hearing loss lawsuits, claiming the cases will be too different to benefit from pretrial coordination.
Plaintiffs say Horizon has failed to share key financial projections to shareholders of what will likely happen if Amgen buys Tepezza manufacturer Horizon Therapeutics
Amgen agreed to buy Horizon as it faces unknown liability from Tepezza lawsuits over hearing loss suffered by users of the thyroid eye disease drug
Lawsuit alleges that the warnings about potential Tepezza hearing loss side effects misled users and doctors, suggesting that the problems were temporary. However, users are reporting irreversible hearing loss caused by Tepezza